Published in Psychiatry (Edgmont) on October 01, 2007
Atomoxetine Augmentation in a Case of Treatment Resistant Panic Disorder with Multiple Augments Failure: A Case Report. Clin Psychopharmacol Neurosci (2015) 0.75
Sulpiride and refractory panic disorder. Psychopharmacology (Berl) (2012) 0.75
Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med (1997) 7.58
Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull (1993) 7.03
A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry (2001) 4.55
Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA (2000) 3.52
Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry (2005) 3.33
Multicenter collaborative panic disorder severity scale. Am J Psychiatry (1997) 3.29
Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry (2005) 3.19
A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry (2005) 2.95
The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2006) 2.63
Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res (2005) 2.61
The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics (2005) 2.37
Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry (2000) 2.18
Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry (1992) 2.15
Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry (1993) 2.08
Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2004) 2.04
Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome. Aust N Z J Psychiatry (2006) 1.98
Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry (1990) 1.84
The structure of genetic and environmental risk factors for anxiety disorders in men and women. Arch Gen Psychiatry (2005) 1.79
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcohol Clin Exp Res (2005) 1.59
Does a U-shaped relationship exist between alcohol use and DSM-III-R mood and anxiety disorders? J Affect Disord (2004) 1.49
Treatment of panic attack and risk of major depressive disorder in the community. Am J Psychiatry (2001) 1.45
Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol (2000) 1.27
Cerebral glucose metabolism associated with a fear network in panic disorder. Neuroreport (2005) 1.20
Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry (2004) 1.20
HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety (2007) 1.16
The role of GABA in anxiety disorders. J Clin Psychiatry (2003) 1.13
Brain imaging in anxiety disorders. Expert Rev Neurother (2004) 1.05
The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol (2007) 1.05
Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder. J Consult Clin Psychol (2001) 1.03
The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants. Neuro Endocrinol Lett (2004) 1.03
Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry (1993) 1.03
Changes in cerebral glucose utilization in patients with panic disorder treated with cognitive-behavioral therapy. Neuroimage (2006) 1.02
Brain circuits in panic disorder. Biol Psychiatry (1998) 1.02
Relationship of childhood sexual and physical abuse to anxiety disorders. J Nerv Ment Dis (1995) 1.01
Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety (2005) 0.99
Long-term benzodiazepine users 3 years after participation in a discontinuation program. Am J Psychiatry (1991) 0.96
Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry (1996) 0.96
Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol (2003) 0.95
SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand (2002) 0.94
History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. J Nerv Ment Dis (2002) 0.93
Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv (2003) 0.93
One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: Outcome and predictors of remission. Behav Res Ther (2005) 0.92
Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry (2001) 0.92
Illicit drug use and anxiety disorders: findings from two community surveys. Psychiatry Res (2006) 0.92
The incidence and influence of early traumatic life events in patients with panic disorder: a comparison with other psychiatric outpatients. J Anxiety Disord (2002) 0.91
Panic disorder and medical comorbidity: a review of the medical and psychiatric literature. Bull Menninger Clin (1996) 0.90
Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res (2001) 0.89
Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry (1987) 0.89
Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry (1999) 0.88
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety (2007) 0.87
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry (1998) 0.87
Treatment-resistant panic disorder. CNS Spectr (2004) 0.85
Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther (2002) 0.85
An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry (2006) 0.85
Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Psychiatry Res (1999) 0.85
The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull (2002) 0.84
Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry (1994) 0.84
The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol (2001) 0.84
Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry (1998) 0.83
Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull (1996) 0.83
Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry (1999) 0.82
Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown anxiety disorders research program. J Clin Psychiatry (2001) 0.82
A neuropsychological study of panic disorder: negative findings. J Affect Disord (1998) 0.82
Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry (2006) 0.82
The diagnosis and drug treatment of anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.81
Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive-behavioural therapy: a follow-up study. Psychother Psychosom (2002) 0.81
Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry (2006) 0.81
WCA recommendations for the long-term treatment of panic disorder. CNS Spectr (2003) 0.80
Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. J Clin Psychiatry (1996) 0.80
Methodologies and outcomes from the sertraline multicenter flexible-dose trials. Psychopharmacol Bull (1998) 0.79
The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand (1993) 0.79
Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry (1988) 0.79
Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol (2000) 0.79
Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol (2006) 0.78
Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull (1996) 0.78
Challenge studies in anxiety disorders. Handb Exp Pharmacol (2005) 0.78
Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J Clin Psychopharmacol (2000) 0.78
Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol (2001) 0.77
Vigabatrin and tiagabine might have antipanic properties. J Psychopharmacol (2004) 0.77
Imipramine in the treatment of agoraphobia: dose-response relationships. Am J Psychiatry (1985) 0.77
The Galway Study of Panic Disorder. II: Changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder. J Affect Disord (1992) 0.77
Duloxetine in the treatment of panic disorder. Int J Neuropsychopharmacol (2005) 0.77
Bupropion sustained release for panic disorder. Psychopharmacol Bull (2003) 0.77
The use of the Panic and Agoraphobia Scale in a clinical trial. Psychiatry Res (1998) 0.77
Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan--implications for management by family doctors. Med J Malaysia (2000) 0.77
Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci (1992) 0.76
Alprazolam in panic disorder: a retrospective analysis. Prog Neuropsychopharmacol Biol Psychiatry (1993) 0.76
Combined pharmacotherapy and cognitive behavior therapy in the treatment of panic disorder. J Clin Psychopharmacol (1998) 0.76
Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. Am J Psychiatry (1989) 0.76
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry (1994) 0.76
Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry (1992) 0.76
The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol (2002) 0.76
Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry (2008) 3.08
A potential role for thalamocingulate circuitry in human maternal behavior. Biol Psychiatry (2002) 1.81
Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport (2004) 1.69
A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry (2006) 1.42
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry (2005) 1.19
Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol (2004) 0.99
The Social Thoughts and Beliefs Scale: a new inventory for assessing cognitions in social phobia. Psychol Assess (2003) 0.96
Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology (2006) 0.92
Assessing abuse liability in clinical trials. Drug Alcohol Depend (2003) 0.83
Recognition and treatment of obsessive-compulsive disorder. J Clin Psychiatry (2007) 0.81
Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry (2008) 0.79
Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry (2009) 0.78
A preliminary investigation of the effects of cognitive behavioral therapy for panic disorder on gastrointestinal distress in patients with comorbid panic disorder and irritable bowel syndrome. Depress Anxiety (2011) 0.78
Posttraumatic stress disorder: characteristics and treatment. J Clin Psychiatry (2008) 0.76
The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry (2004) 0.75
Citalopram treatment of paroxetine-intolerant depressed patients. Depress Anxiety (2002) 0.75